Coloplast A/S : Governance and key risks

Coloplast's ESG event

22 March 2022

Governance and key risks

Kirsten,

Denmark

Anders Lonning-Skovgaard

Executive Vice President, CFO

Making life easier

Coloplast has a two-tier management structure comprising the Board of Directors and the Executive Leadership Team

Governance structure

Board of Directors

Consists of six shareholder-elected and three employee-elected members

Audit	Remuneration and
Committee	Nomination Committee
Consists of three BoD members	Consists of four BoD members

Executive Leadership Team

Consists of CEO, CFO, Global Operations, Innovation, Growth, and People & Culture

2 |

Composition of Board of Directors

Board member	Nationality	Gender	Independent	Audit	Rem. & Nomin.
Committee	Committee
Lars Rasmussen, Chairman1	Danish	Male	No
Niels Peter Louis-Hansen,	Danish	Male	No
Deputy Chairman1
Carsten Hellmann1	Danish	Male	Yes
Annette Brüls1	Belgian	Female	Yes
Jette Nygaard-Andersen1	Danish	Female	Yes
Marianne Wiinholt1	Norwegian	Female	Yes
Thomas Barfod2	Danish	Male	No
Nikolaj Kyhe Gundersen2	Danish	Male	No
Roland Vendelbo Pedersen2	Danish	Male	No

Composition of Executive Leadership Team

Executive Leadership Team Nationality	Gender	Executive Leadership Team Nationality	Gender
Kristian Villumsen, President	Danish	Male	Paul Marcun,	Australian	Male
& CEO	EVP Growth
Anders Lonning-Skovgaard,	Danish	Male	Camilla G. Møhl,	Danish	Female
EVP & CFO	SVP People & Culture3
Nicolai Buhl Andersen, EVP	Danish	Male	Allan Rasmussen, EVP Global	Danish	Male
Innovation	Operations

1. Shareholder-elected board member

2. Employee-elected board member

3. Until 30 April, 2022

The Coloplast organisation is divided into Chronic Care and Strategic Business Units, running on shared global business support functions

Coloplast Group

Chronic Care

Strategic Business Unit

Ostomy CareContinence Care

Wound

& Skin Care

Interventional	Voice & Respiratory
Urology	Care

Marketing	Marketing
Sales Regions	Sales Regions

R&D

Global Operations

Global Business Support Functions

•	Marketing	•	Marketing
•	Sales	•	Sales
•	R&D	•	R&D
•	Operations	•	Operations

Part of the ongoing integration

3 |

We have a standardised risk reporting and governance process, involving the Board of Directors and Executive Leadership Team

Risk governance structure

Board of Directors

Monitors overall risk landscape

Reviews conclusions and recommendations submitted by ELT

Executive Leadership Team

Defines overall risk profile

Launches and approves activities to address most significant risks

CFO

Overall responsible for risk management process and operations

Group Risk Management

Responsible for the risk reporting process

Submits quarterly risk update to ELT

Business units and group functions

Identifies, assesses, and manages risks in their specific area

Reports key risks quarterly to Group Risk Management

Key risk categories for Coloplast over a five-year horizon*

Impact	PBC	PR
		CRR

LC

PIDPQS

CLR

	Likelihood
LC - Legal and compliance	PID - Product innovation and development
PR - Pricing and reimbursement	PBC - Production and business continuity
PQS - Product quality and safety	CRR - Cyber
CLR - Climate

4 |	* Except for Climate change risk, which is considered a long-term risk spanning
beyond five years

ESG reporting is defined by external standards and requirements, and ESG related metrics are reported on a regular basis

Our disclosures and reporting of ESG metrics is defined by external standards

EU Taxonomy

Rankings performed by third-party agencies put Coloplast's ESG efforts ahead of the curve1

Relative position

1 out of 59

in Medical Supplies

AA

B-

Reporting of ESG metrics is now done on a quarterly basis2

ESG metric included in the short term incentive for the ELT and the broader HQ organization

Organic	EBIT	Climate
Growth	Margin	related KPI
45%	45%	10%

5 |	1.	Latest rankings from 2021
	2.	ESG metrics are audited on a yearly basis